Halaven filed in EU for earlier-line breast cancer
This article was originally published in Scrip
Eisai has filed a marketing authorization application in the EU for its novel oncology drug Halaven (eribulin mesylate) in the earlier line treatment of metastatic breast cancer, in a move that could open up a broader therapeutic and commercial market for the microtubule dynamics inhibitor.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.